Actively Recruiting

Phase 2
Age: 20Years +
All Genders
NCT06383013

BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

Led by Blue Blood Biotech Corp. · Updated on 2026-04-22

96

Participants Needed

5

Research Sites

243 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.

CONDITIONS

Official Title

BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

Who Can Participate

Age: 20Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female, at least 20 years of age at screening
  • Able to understand the study and provide written informed consent
  • Willing to follow ulcer care regimen and attend all study visits
  • Diagnosed with Type 1 or Type 2 diabetes and under physician care
  • Glycosylated hemoglobin (HbA1c) of 12% or less
  • At least one diabetic foot ulcer located below the knee that has not healed for 4 weeks or more
  • Target ulcer size between 0.5 cm² and 10 cm² confirmed at screening and randomization visits
  • Target ulcer classified as Grade 1 or 2 by Wagner Classification, without signs of infection
  • Adequate blood flow to affected limb shown by specific oxygen or pressure tests
  • Adequate liver function (ALT and AST ≤ 2 times upper limit of normal) and kidney function (serum creatinine ≤ 3 mg/dL)
  • Adequate blood counts: ANC ≥ 1,500 cells/µL, WBC ≥ 3,000 cells/µL, platelets ≥ 100,000/µL, hemoglobin ≥ 10 g/dL for males or ≥ 9 g/dL for females
  • Negative pregnancy test for females within 28 days before treatment
  • Use of appropriate contraception during treatment and for 4 weeks after stopping for males and females of childbearing potential
Not Eligible

You will not qualify if you...

  • Signs or symptoms of infection in the target ulcer, including swelling, redness over 0.5 cm, tenderness, warmth, or pus
  • Cellulitis or gangrene in the lower leg or foot with the target ulcer
  • Active bone infection (osteomyelitis) requiring antibiotics within 1 week before screening
  • Ulcer size changed by 30% or more after 2 weeks of standard care before randomization
  • Another open ulcer less than 2 cm from the target ulcer on the same leg or foot
  • Ulcer caused mainly by conditions other than diabetes
  • Ulcers related to incompletely healed amputation wounds
  • Structural deformities or conditions preventing proper off-loading of ulcer
  • Use of certain medications or treatments within specified timeframes including growth factors, systemic corticosteroids, immunosuppressants, radiation, chemotherapy, skin grafts, hyperbaric oxygen, topical antimicrobials, or enzymatic debridement
  • History or current cancer except certain treated skin or cervical cancers without recurrence
  • Vasculitis, connective tissue diseases, or other conditions impairing ulcer healing besides diabetes
  • Sickle cell disease
  • Significant abnormal electrocardiogram findings
  • Poor nutrition (serum albumin < 2.5 g/dL)
  • High C-reactive protein (> 50 mg/dL)
  • History of drug or alcohol abuse per DSM-5
  • Positive HIV test
  • Lactating females during the study
  • Medical, mental, or psychological conditions interfering with study compliance or participation as judged by investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

National Cheng Kung University Hospital

Tainan, Taiwan

Actively Recruiting

2

Shin Kong Wu Ho-Su Memorial Hospital

Taipei, Taiwan

Actively Recruiting

3

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Taipei, Taiwan

Actively Recruiting

4

Wanfang Hospital

Taipei, Taiwan

Not Yet Recruiting

5

Linkou Chang Gung Memorial Hospital

Taoyuan, Taiwan

Actively Recruiting

Loading map...

Research Team

C

Cassie Chuang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers | DecenTrialz